KDR and non-small cell lung carcinoma: BOS172738 is an investigational compound with potent selectivity against RET, spares VEGFR2 activity, overcomes the RET-G810 resistance mutation, and displays a favorable safety profile when administered as a single-agent to patients with RET fusion-positive NSCLC or MTC tumors (282).